Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 380

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 380
---
,273  
  Total non-current R& D incentives receivables - discounted value        €                         33,358      27,062      20,684      17,884      33,741      132,729  

19. Inventories

The following table provides an overview of our inventories by type of inventory:

                              December 31,                                  
                              2024                                          
 ────────────────────────────────────────────────────────────────────────────
                              (Euro, in thousands)                          
  Raw materials               €                         51,192      55,263  
  Semi-finished products                                —           12,598  
  Finished products                                     —            6,117  
  Total inventories           €                         51,192      73,978  

Our inventory consisted in full out of Jyseleca® products.

F-46

Table of Contents

20. Trade and other receivables and other current assets
December 31,
2024
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
(Euro, in thousands)
Trade receivables € 32,471 17,494
Current contingent consideration receivable 4,742 - 
Prepayments 103 738
Other receivables 10,160 10,217
Trade and other receivables 47,476 28,449
Accrued income 835 508
Deferred charges 30,214 14,632
Other current assets 31,049 15,140
Total trade and other receivables & other current assets € 78,525 43,589
The carrying value of trade and other receivables & other current assets approximate their fair value.
The increase in deferred charges mainly related to $15.0million in R& D funding paid to Adaptimmune which will gradually be released in R& D expenses over the R& D period.
We refer to note 5 for more information on the current contingent consideration receivable.
On December 31, 2024, we had a provision for expected credit losses of €9.6million, fortwodisputed invoices. We did not account for a provision for expected credit losses relating to all our other trade and other receivablessince we don’t have a history of credit losses and we are not aware of any forward-looking information that could materially influence the credit risk. 21. Non-current and current financial investments
December 31,
2024